BNKL (Bionik Laboratories) WACC %:7.29% (As of Jul. 04, 2026)


BNKL Bionik Laboratories Corp BNKL
12 GF Score
Price $0.00
View Full Analysis

What is Bionik Laboratories WACC %?

Bionik Laboratories BNKL -99.00% 12 WACC % is 7.29% as of Jul. 04, 2026. GuruFocus rates BNKL with a GF Score™ of 12/100.

As of today (2026-07-04), Bionik Laboratories's weighted average cost of capital is 7.29%%. Bionik Laboratories's ROIC % is 0.00% (calculated using TTM income statement data). Bionik Laboratories earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Bionik Laboratories  (OTCPK:BNKL) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Bionik Laboratories's weighted average cost of capital is 7.29%%. Bionik Laboratories's ROIC % is 0.00% (calculated using TTM income statement data). Bionik Laboratories earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Bionik Laboratories WACC % Historical Data

* Premium members only.

The historical data trend for Bionik Laboratories's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionik Laboratories WACC % Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.58 -6.29 -0.70 9.18 0.64

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.18 4.80 7.44 1.77 0.64

BNKL vs ARPC, GRST, IONM: WACC % Comparison

For the Medical Care Facilities subindustry, Bionik Laboratories's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionik Laboratories WACC % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's WACC % distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's WACC % falls into.


BNKL
12GF Score
Bionik Laboratories Corp BNKL
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionik Laboratories WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Bionik Laboratories's market capitalization (E) is $0.000 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2023, Bionik Laboratories's latest one-year quarterly average Book Value of Debt (D) is $1.4538 Mil.
a) weight of equity = E / (E + D) = 0.000 / (0.000 + 1.4538) = 0
b) weight of debt = D / (E + D) = 1.4538 / (0.000 + 1.4538) = 1

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.485%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Bionik Laboratories's beta is -67.0612.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.485% + -67.0612 * 6% = -397.8822%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2023, Bionik Laboratories's interest expense (positive number) was $0.106 Mil. Its total Book Value of Debt (D) is $1.4538 Mil.
Cost of Debt = 0.106 / 1.4538 = 7.2912%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -4.945 = 0%.

Bionik Laboratories's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0*-397.8822%+1*7.2912%*(1 - 0%)
=7.29%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 7.29% mean?
Bionik Laboratories (BNKL) has a WACC % of 7.29% as of Jul. 04, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Bionik Laboratories and its competitors.
Is Bionik Laboratories' WACC % too high?
Bionik Laboratories' current WACC % is 7.29%. The Healthcare Providers & Services industry median WACC % is 8.53. Bionik Laboratories' value of 7.29% is 14.5% below this industry median. Overall, Bionik Laboratories has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionik Laboratories' WACC % compare to ARPC and GRST?
Bionik Laboratories' WACC % of 7.29% can be compared against companies in the Healthcare Providers & Services industry. The industry median WACC % is 8.53. Bionik Laboratories' value of 7.29% is 14.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Healthcare Providers & Services company?
The median WACC % among Healthcare Providers & Services companies is 8.53, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionik Laboratories's current WACC % of 7.29% is 14.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Bionik Laboratories and its competitors. For the Healthcare Providers & Services industry, the median WACC % is 8.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionik Laboratories's current WACC % is 7.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionik Laboratories stock overvalued right now?
Bionik Laboratories (BNKL) has a current WACC % of 7.29%. The current WACC % is 7.29% and 14.5% below the Healthcare Providers & Services industry median of 8.53. Bionik Laboratories' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Bionik Laboratories (BNKL), the current WACC % is 7.29% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionik Laboratories Business Description

Address 80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
12GF Score

Get the complete analysis for BNKL

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price